Deciphering the Transmission Dynamics of Carbapenemase Genes in Carbapenem-Resistant Enterobacter cloacae

Study Background and Research Question

Carbapenem-resistant Enterobacteriaceae (CRE) have become an urgent global public health concern, driven by the rapid emergence and dissemination of resistance determinants in clinical settings. Among these, carbapenem-resistant Enterobacter cloacae (CREC) is of particular epidemiological significance, ranking third among CRE in China. The COVID-19 pandemic, with its associated increase in antibiotic use and disruption of healthcare workflows, has further complicated the landscape of antibiotic resistance, raising critical questions about the molecular mechanisms and epidemiology of resistance gene spread. Chen et al. (2025) sought to characterize the prevalence, genetic localization, and transmission potential of carbapenemase-encoding genes (CEGs) in CREC isolates collected from eight tertiary hospitals in Guangdong province during the pandemic period (Chen et al., 2025).

Key Innovation from the Reference Study

This study delivers a uniquely comprehensive analysis of CEGs in CREC, integrating molecular detection, plasmid elimination, conjugation assays, and epidemiological correlations across a representative regional hospital network. Unlike prior reports that focused primarily on single-site prevalence or genotype surveys, this work elucidates both the chromosomal and plasmid-based carriage of key resistance genes—particularly blaNDM-1—and explores their transfer dynamics within and between clinical settings. The high-resolution mapping of mobile genetic elements and genotypes, combined with stratified epidemiological data, provides a nuanced framework for interpreting the ongoing evolution of multidrug resistance in Enterobacter species.

Methods and Experimental Design Insights

The investigators collected 54 non-duplicate CREC isolates from eight teaching hospitals in Guangdong between December 2022 and June 2024. Plasmid elimination was performed using a variable temperature sodium dodecyl sulfate (SDS) approach, enabling discrimination between chromosomal and plasmid-encoded resistance genes. Polymerase chain reaction (PCR) assays targeted key CEGs, specifically blaNDM-1, blaIMP, and blaKPC-2, to determine their presence and genetic context. Broth microdilution was applied for antimicrobial susceptibility testing, differentiating the resistance phenotypes of CEG-positive versus CEG-negative isolates. Plasmid conjugation experiments assessed the horizontal transferability of resistance determinants, while enterobacterial repetitive intergenic consensus PCR (ERIC-PCR) and NTSYS software facilitated genotyping and cluster analysis. Detailed epidemiological data were collected to align molecular findings with patient demographics, clinical departments, and specimen sources.

Core Findings and Why They Matter

The study's findings underscore the dominance of plasmid-mediated resistance in the current clinical landscape. Among the isolates:

• 85.19% carried CEGs, with blaNDM-1 present in 33.33% of strains on both chromosomes and plasmids, and in 46.30% exclusively on plasmids.
• A small subset harbored blaIMP (3.70%) or both blaNDM-1 and blaKPC-2 (1.85%) on plasmids.
• Resistance rates to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin were significantly higher among CEG-positive isolates (Chen et al., 2025).
• Plasmid conjugation demonstrated efficient horizontal gene transmission, with a 95.65% overall success rate for CEG transfer and especially high rates for blaNDM-1 and blaIMP.
• Six types of mobile genetic elements were identified, with ISEcp1 being the most prevalent (87.04%). Notably, 40.74% of CREC strains carried four types of mobile elements simultaneously, increasing the potential for multi-gene dissemination.
• Genotyping revealed 17 distinct clusters, with types E and G being the most frequent, indicating local clonal expansion and possible interdepartmental transmission.
• Epidemiologically, CEGs were most commonly detected in male and elderly patients, within respiratory medicine wards, and in sputum samples, highlighting clinical risk factors for multidrug-resistant CREC emergence.

These findings clarify that plasmid-borne carbapenemase genes—particularly blaNDM-1—are a primary driver of both vertical and horizontal multidrug resistance in Enterobacter cloacae, with major implications for infection control and the development of laboratory models for antibiotic resistance research.

Comparison with Existing Internal Articles

The molecular and epidemiological insights from Chen et al. (2025) directly expand on the themes presented in recent literature. For instance, the internal review "Carbapenemase Genes in CREC: Epidemiology and Transmission in Guangdong" summarizes early regional findings on CEG prevalence and transmission, which are now substantiated and extended by the current high-resolution mapping of plasmid- and chromosome-borne resistance. Similarly, "Carbapenemase Genes in Enterobacter cloacae: Genomic Dynamics in Guangdong Hospitals" discusses the role of mobile genetic elements in resistance dissemination, closely aligning with the detailed identification of ISEcp1 and other elements in the reference study. The integration of molecular typing and epidemiological risk stratification in the Chen et al. paper represents a methodological advance over these prior syntheses, offering a more actionable blueprint for resistance surveillance and laboratory assay design.

From an experimental perspective, the internal resource "Ertapenem Sodium Salt: Bench Protocols for Resistance Research" provides practical guidance for antibacterial agent selection, susceptibility testing, and resistance workflow optimization, complementing the molecular epidemiology of Chen et al. by translating resistance gene findings into actionable protocol recommendations.

Limitations and Transferability

While the study provides robust evidence of CEG prevalence and transferability, several limitations warrant consideration. The sample set is geographically limited to Guangdong province and may not capture the full heterogeneity of CREC resistance mechanisms across China or globally. The observational period coincided with the COVID-19 pandemic, a context that may have accelerated certain epidemiological trends. Additionally, while plasmid elimination and conjugation experiments offer strong evidence for horizontal transfer, in vivo transfer dynamics and clinical outcomes were not directly assessed. Nonetheless, the protocols and core findings are highly transferable to other molecular microbiology settings, especially for laboratories seeking to model resistance gene spread or benchmark the efficacy of antibacterial agents against multidrug-resistant Gram-negative pathogens.

Protocol Parameters

• Broth microdilution for susceptibility testing: Prepare serial dilutions of Ertapenem sodium salt in cation-adjusted Mueller-Hinton broth; typical starting concentrations align with MIC90 thresholds reported for Enterobacteriaceae (≤1 mg/L).
• Plasmid elimination (SDS method): Incubate isolates at variable temperatures with 0.1% SDS for 18–24 hours to facilitate loss of plasmid-borne CEGs before PCR-based localization.
• Conjugation assays: Mix donor and recipient strains in a 1:1 ratio on a non-selective agar surface for 6–8 hours, then plate onto selective media containing Ertapenem or other relevant antibiotics.
• PCR detection of CEGs: Use validated primer sets for blaNDM-1, blaIMP, and blaKPC-2; amplify DNA from both whole-cell lysates and plasmid preparations.
• Genotyping (ERIC-PCR): Employ standard ERIC primers; cluster analysis can be performed using NTSYS or comparable software to delineate strain relatedness.
• Sample stratification: Record patient demographic, clinical department, and specimen type data to align molecular results with epidemiological risk factors.

Research Support Resources

For laboratories conducting antibiotic resistance profiling or modeling the transmission of carbapenemase-producing Enterobacteriaceae, the use of Ertapenem sodium salt as a standardized antibacterial agent is well-supported by both the reference study and established protocols. Ertapenem (sodium salt) (SKU C3451) is a broad-spectrum carbapenem antibiotic that offers reliable activity against both Gram-positive and Gram-negative bacteria, facilitating reproducible susceptibility and resistance experiments. Its pharmacokinetics and spectrum of activity are particularly suited for high-throughput assays and resistance mechanism research. Researchers can optimize their workflows by leveraging the detailed protocol guidance found in recent internal articles, ensuring accurate modeling of resistance gene dissemination and antibiotic efficacy.